Vitamin markets: Niacin manufacturer claims force majeure due to a fire at plant
On February 14 2025 one of the vitamin B3 manufacturers has had a fire in their niacin factory. No injuries or casualties were reported. The niacinamide factory is still up and running. Force majeure has been claimed by the manufacturer of niacin. Learn more in this week’s feed additive snapshot (week 8).
Vitamin E 50%
Vitamin E prices have remained stable to slightly weak, even as suppliers attempt to implement price hikes and manage availability. The current inventory appears to be adequate, allowing prices to hold steady at this time and even weaken a bit. Contracts for the first quarter are in place, and a portion of the second quarter has also been secured.
Vitamin A 1000
The market is experiencing a stable to weak phase, with a continued weakish outlook because of anticipated increased capacity from China, coupled with a Western supplier still under force majeure but expected to resume operations, and therefore additional volume, later this year. Buyer activity appears cautious and there is a wait-and-see attitude. Q1 is contracted.
Vitamin D3 500
Vitamin D3 prices continue to be elevated due to material shortages and suppliers offering firm prices. However, with the majority of materials now contracted for immediate consumption, market activity has slowed, resulting in fewer transactions. The upcoming period should provide clearer insight into whether these elevated prices will be sustained, as contracts for the first quarter have been established and a portion of the second quarter has also been secured.
Vitamin B2 80%
Although manufacturers still express a desire to raise prices, the market remains stable and appears well-balanced. In Europe, a slight decline in prices has even been observed, while in other regions, prices have remained consistent for an extended period. No significant changes are anticipated in the near future, and the first quarter is now fully contracted.
D-Calpan
In all regions, the market remains quite stable regarding actual transaction prices and the market price continues to be low. While some key suppliers of d-calpan are eager to see prices rise, the prevailing oversupply has so far prevented a shift from the current pricing structure, and no significant changes are anticipated in the near future. The first quarter and part of the second quarter are already contracted.
Vitamin B3
On February 14 2025 one of the vitamin B3 manufacturers has had a fire in their niacin factory. No injuries or casualties were reported. The niacinamide factory is still up and running. Force majeure has been claimed by the manufacturer of niacin. The damage is said to be severe and it might take considerable time to restore. So far the market has not responded by significant new activity. A bit more transactions have been seen and so far the recent price decline has stopped. No elevated prices have been seen yet.
Biotin
The biotin market has remained stable for several months, continuing to hover at a historically low level. Suppliers have made multiple attempts to raise prices, yet none have succeeded thus far. Currently, the market appears balanced, and no significant changes are anticipated in the near future. Contracts for Q1 are secured, along with a portion of Q2.
Vitamin C 35% mono
The eagerness of suppliers to raise prices is evident, whether through actual price hikes or by withholding offers. Although some suppliers also offer lower prices now FOB China, compared to several weeks ago. This situation has created a patience game between suppliers and buyers, as the market remains stable with little expected nearby change. A significant portion of Q1 and Q2 has already been contracted.
